Immunology & Inflammation

Shop By

Items 201-226 of 226

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. IFN-α and IFNAR interaction inhibitor

    IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR; inhibit MVA-induced IFN-α responses by BM-pDCs (IC50=2-8 uM).
  2. Arginase inhibitor

    nor-NOHA acetate is a specific and reversible arginase inhibitor, induces apoptosis in ARG2-expressing cells under hypoxia but not normoxia.
  3. tubulin polymerisation inhibitor

    Lexibulin 2Hcl (CYT-997 2Hcl) is a potent tubulin polymerisation inhibitor with IC50 of 10-100 nM in cancer cell lines; with potent cytotoxic and vascular disrupting activity in vitro and in vivo.
  4. COX-2 inhibitor

    Etoricoxib D4 (MK-0663 D4) is a deuterium labeled Etoricoxib. Etoricoxib is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.
  5. HDAC inhibitor

    Sulforaphane activates Nrf2 and inhibits high glucose-induced progression of pancreatic cancer via AMPK dependent signaling. Sulforaphane has shown anti-cancer and anti-inflammatory activities.
  6. IL-12/IL-23 inhibitor

    Apilimod (STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively.
  7. NADPH oxidase inhibitor

    APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively.
  8. TLR4 inhibitor

    TLR4-IN-C34 is an orally active TLR4 inhibitor and reduces systemic inflammation in models of endotoxemia and necrotizing enterocolitis.
  9. PD-1/PD-L1 interaction inhibitor

    BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM.
  10. NLRP3 inhibitor

    MCC950 (CP-456773, CRID3) is a potent and selective inhibitor of NLRP3 (NOD-like receptor (NLR) family, pyrin domain-containing protein 3) with IC50 of 7.5 nM and 8.1 nM in BMDMs and HMDMs, respectively.
  11. Nrf2 inhibitor

    AEM1 is an inhibitor of deregulated NRF2 transcriptional activity in cancer.
  12. CCR8 inhibitor

    R243 is an inhibitor of CCR8 signaling and chemotaxis.
  13. allosteric inhibitor of CXCR1 and CXCR2

    SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2.
  14. ROS1/NTRK inhibitor

    Taletrectinib (DS-6051b) is a potent, orally active, and new-generation selective ROS1/NTRK inhibitor.
  15. CD73 Inhibitor

    LY-3475070 is a potent and selective CD73 Inhibitor with IC50 of 28 nM.
  16. JAK3/STAT5 inhibitor

    BD750, an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC50 values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively.
  17. IRAK4 inhibitor

    IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor extracted from patent CN107163044A, Compound15, has an IC50 of 2.8 nM.
  18. nNOS inhibitor

    7-Nitroindazole, a heterocyclic compound, acts as a selective inhibitor for neuronal nitric oxide synthase showing a 10-fold selectivity for neuronal NOS.
  19. TLR7/9 inhibitor

    E6446 is an inhibitor os Toll-like receptor (TLR)7 and 9 signaling.
  20. COX-1/COX-2 inhibitor

    CAY10404 is one of the most selective inhibitors of COX-2 over COX-1.
  21. IL-2 inhibitor

    SU5201 is an inhibitor of interleukin-2 (IL-2) production.
  22. COX-1 inhibitor

    Mofezolac, a non-steroidal anti-inflammatory drug (NSAID), is a selective, reversible and orally active COX-1 inhibitor with an IC50 of 1.44 nM.
  23. COX inhibitor

    Pamicogrel (KBT3022) is a cyclooxygenase (COX) inhibitor.
  24. sulfiredoxin inhibitor

    J14 is a reversible sulfiredoxin inhibitor with an IC50 of 8.1 μM. J14 induces oxidative stress (intracellular ROS accumulation) by inhibiting sulfiredoxin, leading to cytotoxicity and cancer cell death.
  25. Complement factor C3 inhibitor

    POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research
  26. CKLF1/CCL17 inhibitor

    CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with CCR4, and inhibits chemotaxis induced by both CKLF1 and CCL17. CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4.

Items 201-226 of 226

Page
per page
Set Descending Direction